Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VKTX Viking Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VKTX
Price (delayed)
$28.43
Market cap
$3.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.15
Enterprise value
$3.16B
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and
Highlights
The company's quick ratio rose by 48% YoY and by 32% QoQ
Viking Therapeutics's debt has decreased by 15% YoY and by 11% QoQ
The net income fell by 37% YoY and by 17% QoQ
The EPS has declined by 24% year-on-year and by 14% since the previous quarter
Key stats
What are the main financial stats of VKTX
Market
Valuations
Earnings
Shares outstanding
112.31M
Market cap
$3.19B
Enterprise value
$3.16B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.77
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$172.32M
Net income
-$128.24M
EBIT
-$128.24M
EBITDA
-$127.85M
Free cash flow
-$133.99M
Per share
Balance sheet
Liquidity
EPS
-$1.15
EPS diluted
-$1.15
Free cash flow per share
-$1.2
Book value per share
$7.55
Revenue per share
$0
TBVPS
$7.74
Total assets
$866.99M
Total liabilities
$20.08M
Debt
$1M
Equity
$846.92M
Working capital
$846.45M
Debt to equity
0
Current ratio
44.25
Quick ratio
43.52
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-14%
Return on equity
-14.4%
Return on invested capital
-15.1%
Return on capital employed
-15.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VKTX stock price
How has the Viking Therapeutics stock price performed over time
Intraday
3.76%
1 week
3.19%
1 month
20.47%
1 year
-58.83%
YTD
-29.35%
QTD
17.72%
Financial performance
How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$172.32M
Net income
-$128.24M
Gross margin
N/A
Net margin
N/A
Viking Therapeutics's operating income has plunged by 51% YoY and by 14% from the previous quarter
The net income fell by 37% YoY and by 17% QoQ
Price vs fundamentals
How does VKTX's price correlate with its fundamentals
Growth
What is Viking Therapeutics's growth rate over time
Valuation
What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
3.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 24% year-on-year and by 14% since the previous quarter
The P/B is 33% less than the last 4 quarters average of 5.6
VKTX's equity is down by 9% year-on-year and by 3.8% since the previous quarter
Efficiency
How efficient is Viking Therapeutics business performance
The ROIC has grown by 32% year-on-year but it has declined by 14% since the previous quarter
Viking Therapeutics's ROE has increased by 22% YoY but it has decreased by 19% from the previous quarter
VKTX's ROA is up by 21% year-on-year but it is down by 20% since the previous quarter
Dividends
What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VKTX.
Financial health
How did Viking Therapeutics financials performed over time
VKTX's current ratio has surged by 50% year-on-year and by 34% since the previous quarter
The company's quick ratio rose by 48% YoY and by 32% QoQ
Viking Therapeutics's debt is 100% lower than its equity
Viking Therapeutics's debt has decreased by 15% YoY and by 11% QoQ
VKTX's equity is down by 9% year-on-year and by 3.8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.